ArticleCell research2012
Revealing a steroid receptor ligand as a unique PPARγ agonist.
Article in Cell research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Structural basis for diosgenin as an inverse agonist of retinoic acid receptor-related orphan receptor γ.Scientific reports · 2026Article
- Article
- Conditional Inhibition of Eip75B Eliminates the Effects of Mating and Mifepristone on Lifespan in FemaleCells · 2024Article
- Effects of mifepristone on adipocyte differentiation in mouse 3T3-L1 cells.Cellular & molecular biology letters · 2024Article
- Article
- Article
- Mifepristone Increases Life Span in FemaleFrontiers in aging · 2022Article
- Tuberculosis alters immune-metabolic pathways resulting in perturbed IL-1 responses.Frontiers in immunology · 2022Article
- Mifepristone Increases Life Span of Virgin FemaleFrontiers in genetics · 2021Article
- A structural perspective on nuclear receptors as targets of environmental compounds.Acta pharmacologica Sinica · 2015Review
- Targeting nuclear receptors with marine natural products.Marine drugs · 2014Review
- Article
- Mifepristone promotes adiponectin production and improves insulin sensitivity in a mouse model of diet-induced-obesity.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Peroxisome proliferator-activated receptor gamma (PPARγ) regulates metabolic homeostasis and is a molecular target for anti-diabetic drugs. We report here the identification of a steroid receptor ligand, RU-486, as an unexpected PPARγ agonist, thereby uncovering a novel signaling route for this steroid drug. Similar to rosiglitazone, RU-486 modulates the expression of key PPARγ target genes and promotes adipocyte differentiation, but with a lower adipogenic activity. Structural and functional studies of receptor-ligand interactions reveal the molecular basis for a unique binding mode for RU-486 in the PPARγ ligand-binding pocket with distinctive properties and epitopes, providing the molecular mechanisms for the discrimination of RU-486 from thiazolidinediones (TZDs) drugs. Our findings together indicate that steroid compounds may represent an alternative approach for designing non-TZD PPARγ ligands in the treatment of insulin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.